Overview of Sirturo

Quick Facts

Property	Description
Active ingredient	Bedaquiline (as fumarate salt)
Form	Oral tablet
Pharmacological class	Diarylquinoline antimycobacterial
Mechanism principle	Inhibition of mycobacterial ATP synthase
Origin	Synthetic derivative, first in its class in decades

What Type of Medicine is Sirturo (Bedaquiline)?

Sirturo is the brand name for the active ingredient bedaquiline, which is structurally classified as a diarylquinoline antimycobacterial. This specialized compound is a synthetic derivative and holds distinction as the first drug of its novel class approved in over forty years specifically to combat certain mycobacterial infections. It is included in therapeutic guidelines for complicated regimens.

As an antituberculosis agent, its status as a specialized, prescription-only medication underscores its use in clinical settings where an effective combination treatment cannot be provided using older agents. The fact that bedaquiline employs a new mode of action means it offers a therapeutic option when resistance mechanisms challenge traditional anti-infective medications.

Composition, Form, and General Purpose

The medication is formulated for oral use as a tablet and contains bedaquiline as the single active ingredient. This compound belongs to the Anatomical Therapeutic Chemical (ATC) category J04AK05, which classifies it as a specialized anti-tuberculosis medicine.

Its general purpose is to provide a specialized component of a necessary combination therapy regimen. This agent achieves a bactericidal effect by targeting and inhibiting the mycobacterial ATP synthase, which is essential for the organism's energy generation. By disrupting the energy supply, bedaquiline provides a means to eliminate persistent or drug-resistant bacterial populations that are difficult to treat with traditional approaches, serving a recognized role in managing complex cases.

What side effects are possible with Sirturo?

Possible Side Effects and Safety Information

The official safety profile for Sirturo (bedaquiline) is structured to classify documented adverse reactions by frequency and potential seriousness, based on clinical data reported to government regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by the incidence observed in clinical trials. The most frequently observed effects are classified as Very Common or Common, affecting various System-Organ Classes (SOCs), including Gastrointestinal, Musculoskeletal, and Nervous systems.

Classification	Examples of Documented Reactions
Very Common (Affects ge 1 in 10)	Nausea, Headache, Arthralgia (joint pain), Vomiting
Common (Affects ge 1 in 100 to < 1 in 10)	Diarrhoea, Dizziness, Myalgia (muscle pain), Insomnia

Serious Safety Concerns and Restrictions

Regulatory documentation highlights two principal serious risks that define the safety characteristics of this medicine:

QTc Prolongation: Sirturo is associated with a risk of QTc interval prolongation, an electrical change in the heart that may be associated with clinically significant ventricular arrhythmia.
Hepatotoxicity: Cases of severe liver injury, including elevations in liver enzymes (Transaminases) and fatal outcomes, have been documented in clinical reports.

Due to these risks, its use is generally restricted in individuals with severe hepatic impairment, severe renal impairment, or certain pre-existing cardiac conditions (e.g., confirmed QTc interval > 450 ms or uncorrected low potassium/magnesium levels). Official labeling also notes that increases in liver enzymes may be slow to appear and can increase gradually throughout the course of the 24-week treatment period.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation states there is no specific clinical experience with the treatment of acute Sirturo (bedaquiline) overdose. Consequently, the emergency management protocol focuses on mitigating the drug’s known severe toxicities, which are expected to be exaggerated in cases of overexposure.

When Urgent Medical Help is Required

Immediate medical attention must be sought for any suspected overdose. Urgent medical care is specifically required if symptoms such as syncope occur, or if a significant ventricular arrhythmia is detected. Help is mandated if ECG monitoring indicates a QTcF interval greater than 500 ms, confirmed by a repeat measurement. It is advised to contact a poison control center for the most current management guidance.

Required Monitoring and Supportive Management

Treatment for overdose is strictly symptomatic and supportive. The regulatory label states that no specific antidote is known for bedaquiline. Due to the drug’s high protein binding (over 99%), removal methods such as dialysis are not likely to significantly remove bedaquiline from the bloodstream.

Officially mandated monitoring procedures include:

Continuous ECG monitoring to assess the QT interval.
Monitoring of vital signs and correction of serum electrolyte abnormalities (potassium, calcium, magnesium).
Monitoring of liver-related laboratory tests (ALT, AST, bilirubin) to assess for severe hepatotoxicity risk.

Therapeutic Uses of Sirturo

Quick Facts: Sirturo Therapeutic Domain

Addresses: Pulmonary multi-drug resistant tuberculosis (MDR-TB).
Use Context: Indicated only as a component of an appropriate combination therapy regimen.
Patient Population: Used in adult and pediatric patients (typically 5 years and older, weighing at least 15 kg).

Sirturo (bedaquiline) is indicated for use as part of a combination regimen to address pulmonary multi-drug resistant tuberculosis (MDR-TB). This medication is typically reserved for instances where an effective treatment regimen cannot be otherwise provided due to documented resistance to standard medications like rifampicin and isoniazid.

Its therapeutic role is to be administered in conjunction with other anti-tuberculosis agents to support the overall treatment of this specific, resistant form of the disease, which affects the lungs. Its use helps to clear Mycobacterium tuberculosis bacteria in affected individuals. Sirturo's role in combination therapy is a key aspect of managing this challenging condition in both adult and pediatric patients (5 years and older, weighing at least 15 kg), providing a crucial therapeutic option.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sirturo?

Regulatory documents establish specific eligibility criteria for Sirturo (bedaquiline) based on patient status and infection type.

Eligibility Scope

Classification	Population/Condition
Populations for whom use is allowed	Adults and pediatric patients 5 years old and 15 kg with pulmonary multi-drug resistant tuberculosis (MDR-TB).
Populations for whom use is contraindicated	Patients with known hypersensitivity to bedaquiline or any tablet excipients.
Populations for whom use is not recommended	Patients with severe hepatic impairment (Child-Pugh Class C). Patients with a baseline QTcF interval > 450 ms or uncompensated heart failure. Breastfeeding mothers.
Use Not Established	Children less than 5 years of age or weighing less than 15 kg. HIV-infected patients with MDR-TB.

Eligibility-Related Restrictions

Use is not authorized for latent tuberculosis, drug-sensitive tuberculosis, extra-pulmonary TB, or infections caused by non-tuberculous mycobacteria. Eligibility is restricted by factors increasing cardiac risk, such as uncorrected electrolyte imbalances and a history of congenital long QT syndrome. Caution is also advised for patients with severe renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sirturo (bedaquiline) can interact with several other medicines and substances, which may affect its effectiveness or increase the risk of side effects. These interactions are primarily related to how the body processes the drug and the drug's effect on heart rhythm.

Interaction Type	Interacting Medicines/Substances
Heart Rhythm (QT Prolongation)	Other QT-prolonging medicines, including certain antibiotics (like fluoroquinolones, macrolides, and clofazimine).
Drug Level Decrease	Strong or moderate CYP3A4 inducers, such as rifamycins (e.g., rifampicin, rifapentine, rifabutin) and efavirenz.
Drug Level Increase	Strong or moderate CYP3A4 inhibitors used for more than 14 consecutive days.
Liver Safety Risk	Other hepatotoxic drugs and alcohol

Important Interaction Notes:

Avoid the use of strong and moderate CYP3A4 inducers, as they may reduce the level of Sirturo in the body, which could decrease its effect.
Avoid prolonged use (more than 14 consecutive days) of systemic strong or moderate CYP3A4 inhibitors, as this may increase the level of Sirturo and raise the risk of side effects.
Due to the risk of additive effects on heart rhythm, caution is necessary with other QT-prolonging drugs. Close monitoring, including frequent ECGs, is required if co-administration is necessary.
Avoid other hepatotoxic drugs and alcohol while on Sirturo to reduce the risk of liver-related adverse reactions.

Mechanism of Action

Molecular Targeting of Mycobacterial Energy Production

The core mechanism involves the highly specific inhibition of the F-ATP synthase enzyme, which is necessary for the energy generation of Mycobacterium tuberculosis. Bedaquiline physically binds to the enzyme's c-subunit, arresting its rotation and blocking the flow of protons ( H^+) across the bacterial membrane. This action functionally collapses the proton motive force and shuts down the main ATP synthesis pathway.

Bactericidal Activity via Cellular Energy Deprivation

The cessation of ATP production leads to a rapid and profound depletion of the microorganism's cellular energy, which translates into bactericidal activity. This mechanism is particularly important because the energy deprivation is effective against metabolically dormant (non-replicating) bacteria, achieving a sterilizing activity that targets populations regardless of their division rate.

Constraints by Genetic Evasion and Selectivity

While the mechanism is selective for the microbial enzyme (due to structural differences from the human enzyme), its action can be limited by genetic evasion. This occurs through mutations in the target atpE gene or through the activation of efflux pumps, both of which reduce the drug's effective concentration at the binding site, limiting the energy-depriving action.

Dosage and Administration Information

How Sirturo is Used in Treatment Regimens

Sirturo (bedaquiline) is an oral medication administered strictly as a component of a necessary combination therapy regimen. The treatment follows a standardized, two-phase, 24-week course and requires Directly Observed Therapy (DOT) for administration.

Dosing and Frequency

The official regimen is divided into an initial intensive phase and a subsequent continuation phase.

Phase	Duration	Dose	Frequency
Intensive	Weeks 1-2	400 mg	Once daily
Continuation	Weeks 3-24	200 mg	Three times per week (with at least 48 hours separation)

The entire course of bedaquiline therapy is typically limited to 24 weeks, though some adult regimens may be extended up to 40 weeks based on regional guidance.

Administration Requirements

All doses of Sirturo must be taken with food to ensure the drug is absorbed effectively. Specific instructions guide the proper handling of the different tablet forms: the 100 mg tablet must be swallowed whole with water. However, the 20 mg tablet is available for patients who cannot swallow whole pills, as it can be dispersed, crushed, or split.

Population and Missed Dose Rules

The use of Sirturo is approved for adults and pediatric patients (those aged 5 years and older weighing at least 15 kg), where dosing is determined using weight-based tables. No dose adjustment is required for patients with mild to moderate renal or hepatic impairment.

If a dose is missed during the daily (Weeks 1-2) phase, that dose should not be made up. If a dose is missed during the intermittent (Weeks 3-24) phase, the dose should be taken as soon as possible, and the three-times-per-week schedule should then be resumed.

Recent Clinical Evidence

Sirturo (bedaquiline) is an antimycobacterial agent that is a component of combination therapy for adults and certain pediatric patients (5 years and older, weighing at least 15 kg) with pulmonary multidrug-resistant tuberculosis (MDR-TB).

Pivotal Clinical Trial Findings

Initial regulatory approvals for bedaquiline were based on data from two controlled Phase 2 trials (TMC207-C208 and TMC207-C209) in adult patients with MDR-TB. The primary endpoint studied was sputum culture conversion, which refers to the time it takes for a patient’s sputum to no longer show evidence of live M. tuberculosis bacteria. In the placebo-controlled trial, the addition of bedaquiline to a background regimen was associated with a shorter time to culture conversion at 24 weeks compared to the placebo group.

Confirmatory Phase 3 Data (STREAM Stage 2)

Confirmation of the clinical profile was provided by the large, multi-country Phase 3 STREAM Stage 2 study. This randomized, open-label trial evaluated the use of an all-oral, bedaquiline-containing regimen for 40 weeks compared to a control regimen that included injectable anti-TB medications.

Regimen Comparison	Favorable Outcome (Week 76)	Risk Profile Note
Bedaquiline-containing regimen	82.7% of patients	ECG monitoring for QT prolongation is required.
Injectable-containing control regimen	71.1% of patients	Potential for adverse effects related to injectable agents.

At 76 weeks, the proportion of patients with a favorable outcome—defined as cure or treatment completion—was observed to be higher in the bedaquiline-containing arm (82.7%) compared to the control arm (71.1%) in the modified intent-to-treat analysis.

Safety Observations

Analysis of the initial placebo-controlled trial noted an imbalance in all-cause mortality, with a higher percentage of deaths reported in the bedaquiline group (11.4%) compared to the placebo group (2.5%) over the follow-up period. The cause of this difference has not been fully determined, and close monitoring for safety, particularly for QT prolongation and potential hepatotoxicity, is emphasized in the prescribing information.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Sirturo (FAQ)

Q: How quickly does Sirturo start working after the first dose?

Studies and official information indicate that the medicine's effectiveness is measured by a clinical marker called sputum culture conversion. This refers to the time it takes for a patient's sputum to no longer show evidence of live M. tuberculosis. In clinical studies, patients taking this medicine experienced an average culture conversion time of 83 days.

Q: Can Sirturo be used by people who are not in a hospital setting?

According to the official product information, it is recommended that this medicine be administered under Directly Observed Therapy (DOT). DOT is a method of supervision where a healthcare professional watches the patient take the medicine. This official recommendation for DOT is a common feature of outpatient tuberculosis care programs.

Q: Does Sirturo have a 'black box warning' in the US?

Yes, the U.S. Food and Drug Administration (FDA) has placed a Boxed Warning on this medicine. This warning serves to draw attention to potential serious outcomes, particularly risks related to QT interval prolongation (a change in the heart's electrical activity) and increased mortality observed in clinical trials.

Q: Are there any over-the-counter pain relievers that interact with Sirturo?

Official product information advises that the coadministration of this medicine with other potentially hepatotoxic agents may increase the risk of liver injury. This warning extends to commonly used non-prescription medicines such as acetaminophen.

Q: What research has been done on the long-term effects of Sirturo?

The initial clinical efficacy trials primarily reported results for up to 76 weeks (about 1.5 years) of patient follow-up. Beyond this period, data from observational cohort studies have provided additional information, with some following patient outcomes up to 24 months after the end of treatment.

Q: Is it true that Sirturo requires blood tests throughout treatment?

Yes, regulatory guidelines recommend frequent monitoring during the course of treatment. This includes regular laboratory tests to check for potential changes in the body, such as levels of liver enzymes and bilirubin. These tests are typically performed at baseline (before starting) and monthly while the patient is on treatment.

Q: Do studies show that Sirturo reduces the chance of disease recurrence?

The regulatory trials measure treatment success based on a favorable outcome at 76 weeks, defined as either cure or treatment completion. Furthermore, data from observational cohorts that follow patients after treatment completion have reported information concerning the medicine's impact on disease recurrence rates.

Q: What information should I provide to my doctor before starting Sirturo?

Regulatory guidelines specify that a patient's allergies, complete list of medicines (including over-the-counter drugs and supplements), and specific medical history are required for evaluation before treatment. This history includes records related to heart problems, liver or kidney disease, and HIV status.

Q: Are there specific symptoms that require immediate medical attention while on Sirturo?

The official safety information lists specific symptoms that require prompt evaluation by a healthcare professional. These include signs of liver damage (e.g., yellowing of the skin or eyes, dark urine), a severe allergic reaction, or heart-related symptoms such as a fast or irregular heartbeat or fainting.

Q: What is the typical monitoring schedule for patients on Sirturo?

Regulatory recommendations detail a strict monitoring schedule focused on heart and liver safety. This includes taking an electrocardiogram (ECG) to check the heart rhythm before starting and then at least monthly during treatment. Liver function tests are also required at baseline and monthly while on the medicine.

Q: How does Sirturo affect the likelihood of a person being contagious?

Clinical trials evaluate the medicine's effect by tracking the time to sputum culture conversion, which is the scientific measure indicating when the patient's phlegm tests negative for M. tuberculosis bacteria. Achieving this marker is key to managing infectious risk.

Q: What is the process for a patient to access Sirturo?

Accessing this specialized, high-cost medicine often involves a specific process beyond a standard prescription. In many regions, the prescription must be initiated following consultation from a recognized Tuberculosis Medical Consultant. Patient assistance programs are also commonly involved in the acquisition process.

Q: What kind of specialist usually manages treatment with Sirturo?

According to the official product information, treatment must be started and monitored by a doctor who has specific expertise. This requires a professional who is experienced in the treatment of multidrug-resistant tuberculosis (MDR-TB).

Q: Is fatigue a common general side effect of taking Sirturo?

The official safety information notes that unusual tiredness or weakness are symptoms listed for evaluation, as they may be associated with other potential serious side effects, such as changes in liver function.

Q: Can Sirturo interact with common vitamins or herbal supplements?

Official safety information states that a complete list of all vitamins and nutritional supplements is required for review. The herbal product St. John’s wort is specifically known to interact with the drug and must be avoided.

Q: Can elderly patients use Sirturo safely?

Regulatory documents indicate there is limited clinical data on the use of this medicine in patients 65 years of age and older. Furthermore, official information notes that older age has been associated with a higher risk of QT interval prolongation (a heart rhythm change).

Q: Why is Sirturo generally not recommended during pregnancy?

Official product information states that there are currently no data available from studies on its use in pregnant women, resulting in the general lack of recommendation. Use during pregnancy is reserved for situations where the benefit is considered to outweigh the potential unknown risk.

Q: Is Sirturo available in countries outside of the US and Europe?

Yes, the medicine has received regulatory approvals and is used in various countries outside of the US and Europe, often with the support of the World Health Organization (WHO) treatment guidelines. Examples of local regulatory authorization have been issued in regions like Africa and Asia.

Q: Is it normal to feel a tingling sensation after starting Sirturo?

According to the official product information, numbness and tingling of the arms, hands, legs, or feet have been reported as a potential side effect. This is a type of nerve-related symptom that patients may experience while taking the medicine.

How should Sirturo be stored and disposed of?

How to Store and Dispose of Sirturo (bedaquiline)

Sirturo tablets must be stored at controlled room temperature, maintained between 68 F and 77 F (20 C to 25 C). The medicine must be kept from freezing and should not be stored above 30 C.

Protection and Stability

The tablets must be kept in their original container to protect them from both light and moisture. The medicine must also be stored out of the sight and reach of children to ensure safety. For certain package types, the product must be discarded 180 days after initial opening, according to regulatory guidelines. Any suspension of the 20 mg tablets prepared with water must be consumed immediately and not stored.

Disposal

Patients should consult a healthcare professional regarding the appropriate method for disposing of any unused or outdated Sirturo.

Sirturo